I-2019 Isitayela esitsha 3-Aminopyrazine-2-Carboxylic Acid CAS No. 5424-01-1

Amava olawulo lweeprojekthi ezininzi kwaye enye ukuya kwimodeli ethile yomboneleli yenza ukubaluleka okukhulu konxibelelwano lwentlangano kunye nokuqonda kwethu ngokulula okulindelweyo kwi-2019 New Style 3-Aminopyrazine-2-Carboxylic Acid CAS No. 5424-01-1, Thina bazimisele ukukunika elona xabiso liphantsi kwimarike, elona xabiso liphezulu kunye nenkonzo yokuthengisa entle kakhulu.Wamkelekile ukuba wenze i-bussines kunye nathi, masiphumelele kabini.
Amava olawulo lweeprojekthi ezininzi kwaye enye ukuya kwimodeli ethile yomboneleli yenza ukubaluleka konxibelelwano lombutho kunye nokuqonda kwethu ngokulula okulindelekileyoChina 3-Aminopyrazine-2-Carboxylic Acid kunye 5424-01-1, Iimpahla zethu zithandwa kakhulu kwigama, njengaseMzantsi Melika, i-Afrika, i-Asia kunye nokunye.Iinkampani "zokudala iimveliso zeklasi yokuqala" njengenjongo, kwaye zizame ukubonelela abathengi ngezisombululo ezikumgangatho ophezulu, ukubonelela ngenkonzo yokuthengisa emva kokuthengisa kunye nenkxaso yobugcisa, kunye nenzuzo yomthengi ngamnye, ukudala umsebenzi ongcono kunye nekamva!

I-2'-Methoxy-3'-nitro-biphenyl-3-carboxylic acid isetyenziswe njengendawo ephakathi kwe-Eltrombopag.
I-Eltrombopag, ephuhliswe yi-GlaxoSmithKline (GSK) e-UK kwaye kamva iphuhliswe ngokudibeneyo kunye ne-Novartis eSwitzerland, yeyokuqala kwaye ivunyiwe kuphela i-molecule encinci ye-non peptide TPO receptor agonist emhlabeni.I-Eltrombopag yavunywa yi-US FDA kwi-2008 yonyango lwe-idiopathic thrombocytopenic purpura (ITP), kunye ne-2014 yonyango lwe-anemia ye-aplastic enzima (AA).Ikwalichiza lokuqala elavunywa yi-US FDA kunyango lwe-AA kwiminyaka engama-30 yakutsha nje.
NgoDisemba 2012, i-US FDA ivume i-Eltrombopag yonyango lwe-thrombocytopenia kwizigulane ezine-hepatitis C engapheliyo (CHC), ukwenzela ukuba izigulane ze-hepatitis C ezine-prognosis embi ngenxa yokubala kweplatelet ephantsi inokuqala kwaye igcine unyango oluqhelekileyo lwe-interferon kwizifo zesibindi.NgoFebruwari3, 2014, i-GlaxoSmithKline yabhengeza ukuba i-FDA inike isiqinisekiso sonyango lwe-Eltrombopag kunyango lwe-hemopenia kwizigulane ezine-chemicalbook aplastic anemia (SAA) ezinzima ezingazange ziphendule ngokupheleleyo kwi-immunotherapy.Ngo-Agasti 24, i-2015, i-US FDA ivume i-Eltrombopag yonyango lwe-thrombocytopenia kubantu abadala kunye nabantwana abaneminyaka eyi-1 kunye nangaphezulu kunye ne-immune immune thrombocytopenia (ITP) abangenayo impendulo eyaneleyo kwi-corticosteroids, i-immunoglobulins okanye i-splenectomy.NgoJanuwari4, 2018, i-Eltrombopag yavunywa ukuba ibhalwe e-China kunyango lwe-immune immune thrombocytopenia (ITP).

Amava olawulo lweeprojekthi ezininzi kwaye enye ukuya kwimodeli ethile yomboneleli yenza ukubaluleka okukhulu konxibelelwano lwentlangano kunye nokuqonda kwethu ngokulula okulindelweyo kwi-2019 New Style 3-Aminopyrazine-2-Carboxylic Acid CAS No. 5424-01-1, Thina bazimisele ukukunika elona xabiso liphantsi kwimarike, elona xabiso liphezulu kunye nenkonzo yokuthengisa entle kakhulu.Wamkelekile ukuba wenze i-bussines kunye nathi, masiphumelele kabini.
2019 Isimbo esitshaChina 3-Aminopyrazine-2-Carboxylic Acid kunye 5424-01-1, Iimpahla zethu zithandwa kakhulu kwigama, njengaseMzantsi Melika, i-Afrika, i-Asia kunye nokunye.Iinkampani "zokudala iimveliso zeklasi yokuqala" njengenjongo, kwaye zizame ukubonelela abathengi ngezisombululo ezikumgangatho ophezulu, ukubonelela ngenkonzo yokuthengisa emva kokuthengisa kunye nenkxaso yobugcisa, kunye nenzuzo yomthengi ngamnye, ukudala umsebenzi ongcono kunye nekamva!